Executive Summary
F. Hoffmann-La Roche Ltd. (Roche) appealed a decision that denied an interim injunction against Cipla Ltd. regarding the manufacturing and sale of the generic drug Erlocip, which is based on the patented molecule Erlotinib (Tarceva). The plaintiffs claimed patent rights over this cancer treatment. However, the Delhi High Court dismissed the appeal, finding that the defendant had raised credible challenges to both the validity of the patent and the prima facie case for infringement. Crucially, the court emphasized that public interest in greater access to life-saving drugs must outweigh the interest in granting an injunction.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in F. Hoffmann-La Roche Ltd. vs Cipla Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Nokia Technologies OYvsAssistant Controller of Patents and Designs
Nokia Technologies OY appealed the Assistant Controller's refusal to grant a patent for its system and method for listening to audio content. The appellant argued that the refusal order failed to consider their amended claims and responses to objections raised under Section 3(k).
Indo Overseas FilmsvsUnion Of India
Indo Overseas Films challenged a customs order that included a substantial royalty payment ($12,500) as part of the transaction value of an imported feature film, 'Web of Silence-AIDS'. The petitioner argued that this royalty should be excluded from the assessable value. However, the Madras High Court upheld the customs authority's decision, ruling that since the right to exploit the film was a condition precedent for importation, the associated royalties must be included in determining the duty.
Perenniala Health Care India Private LimitedvsS.Samsen Papli
Perenniala Health Care India Private Limited filed a suit seeking declarations of exclusive rights over the FRANCH trademarks and associated artistic works, along with permanent injunctions against alleged infringement. The plaintiff sought to nullify certain assignment deeds executed by the defendants. However, due to the plaintiff failing to appear or prosecute the case despite court notices, the Madras High Court dismissed the entire suit.
Dr.Reddys Laboratories LimitedvsWest-Coast Pharmaceutical Works Ltd.
In this trademark infringement suit concerning Omeprazole capsules, the Delhi High Court addressed a request for ex parte ad interim relief. While the plaintiff presented an arguable case regarding the deceptive similarity between 'OMEZ' and 'OMES', the court ultimately refused immediate injunction. The judge emphasized that mere prima facie evidence is insufficient; the balance of convenience, irreparable loss, and public interest must be weighed, leading to a decision to allow the defendant a chance to respond.
M/s.Kaleesuwari Refinery Private LimitedvsM/s.Amman Trader
This Madras High Court judgment addressed a trademark dispute where M/s.Kaleesuwari Refinery Private Limited sought permanent injunctions against M/s.Amman Trader for infringing its registered mark 'DHEEPAM' by using 'SRI DEEPAM' on edible oil products, and for passing off inferior goods as the plaintiff's. The parties ultimately reached a Joint Compromise Memo, which was accepted and decreed by the court. This settlement ensures that the defendant will cease all infringing activities related to the plaintiff's brand.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.